Precision Medicine

Precision Medicine

Targeted Oncology presents Precision Medicine, a video series featuring oncology experts discussing how to use a more customized approach when treating patients with cancer.

Advances in Later-Lines of Therapy for GIST

April 23rd 2021

Experts discuss advances in gastrointestinal stromal tumors (GIST) and dive into the evolving landscape and ongoing unmet needs.

Targeting PSMA in Advanced Prostate Cancer

March 30th 2021

Experts in genitourinary oncology discuss emerging research surrounding the clinical utility of phenotypic biomarkers, such as prostate-specific membrane antigen (PSMA), for use in the treatment of metastatic castration-resistant prostate cancer.

Examining TKI Combinations in Advanced RCC

March 30th 2021

A panel discusses the role of TKI combination therapies for patients with advanced renal cell carcinoma and how they have changed the treatment landscape.

HER2+ BC: A Year in Review and Updates from SABCS

January 19th 2021

A review of key relevant data on HER2-positive breast cancer from the 2020 SABCS Virtual Symposium.

Moving Forward in the Management of Acute GvHD

December 23rd 2020

Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.

Evolving Approaches for HCC in the Molecular Medicine Era

November 5th 2020

An in-depth discussion on the targeting of specific molecular pathways with newer, novel therapies to better manage patients with liver cancer.

Targeted Therapy in Early-Stage HER2+ Breast Cancer

July 31st 2020

Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.

Advancing Survival in Relapsed/Refractory Multiple Myeloma

July 28th 2020

A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.

Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer

July 7th 2020

Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.

Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors

July 1st 2020

Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.